Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$285.4MCash on Hand
23.6mo Cash Runway
Follow DNA by emailGet an email when DNA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DNA, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Earnings Reported Q3 2026 revenue of $28 million, down 6% from $29 million a year earlier, with a GAAP net loss from continuing operations of ($41) million and cash, equivalents and marketable securities of $285 million. Signed a first autonomous lab sale to Novo and reaffirmed 2026 cash burn of ($150)-($125) million. Form 8-K · SEC filing · Press release
Oct 29, 2026 ·
Ginkgo Bioworks plans a presentation and Q&A on its third quarter 2026 business performance on Thursday, November 5, 2026, at 4:30 p.m. ET, with a webcast and replay on its investor relations website. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
📊 Drug Pipeline
Drug
Indication
Most advanced trial
Status
Also used in these trials (approved or third-party drugs, not DNA's own candidates): Octreotide Acetate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
DNA holds $285.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.3M/quarter from operations,
an estimated runway of 23.6 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DNA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.